Effect of neonatal administration of Lactiplantibacillus plantarum ATCC 202195 on stool iron content and iron status in infants in Dhaka, Bangladesh
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Lactobacillus probiotics may enhance host iron bioavailability, offering a potential strategy to address iron deficiency; however, evidence of such effects in infants is lacking.
Objective
To examine whether neonatal administration of Lactiplantibacillus plantarum ATCC 202195 (LP202195), with or without fructooligosaccharide (FOS), reduces stool iron content and improves iron status in young infants in Dhaka, Bangladesh.
Methods
This study was a secondary analysis of a randomized placebo-controlled trial in which infants, 0-4 days of age, were randomly allocated to one of five groups: placebo, 1- or 7-day regimens of LP202195, with or without FOS. Fecal iron was quantified in stool samples collected at 14 days postnatal age (n=307) and serum ferritin concentration was measured at 2 months postnatal age (n= 251). Effects of the 1- and 7-day LP202195 regimens were estimated using linear regression and reported as mean percent differences relative to placebo, with 95% confidence intervals (95%CI).
Results
In the combined analysis irrespective of FOS co-administration, there were no differences in fecal iron concentrations following 1-day (% difference=9.8%, 95%CI: −19%, 49%; P=0.54) or 7-days (% difference= −6.1%, 95%CI: −31%, 28%; P=0.69) of LP202195 administration, relative to placebo (geometric mean concentration=4.3mg Fe/100g dry stool (95%CI:3.3, 5.6); n=53). There were no effects of LP202195 administration on serum ferritin concentration following the 1-day (% difference=2.4%, 95%CI: −−22%, 35%; P=0.86) or 7-day (% difference=1%, 95% CI: - 23%, 33%; P=0.94) regimen, relative to placebo (geometric mean concentration=189 ng/mL (95%CI: 155, 232); n=55). Inferences were unchanged when intervention groups were disaggregated by FOS co-administration (P>0.05 for all).
Conclusions
LP202195, when administered neonatally as a probiotic alone or synbiotic with FOS for 1 or 7 days, did not affect stool iron (2 weeks of age) or iron status (2 months of age) in Dhaka, Bangladesh.
Clinical Trial Registry
ClinicalTrials.gov identifier: NCT05180201
